Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:88
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [1] How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension
    Ntiloudi, Despoina
    Zanos, Stavros
    Gatzoulis, Michael A.
    Karvounis, Haralambos
    Giannakoulas, George
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (01) : 11 - 18
  • [2] Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism
    Duffels, M. G. J.
    van der Plas, M. N.
    Surie, S.
    Winter, M. M.
    Bouma, B. J.
    Groenink, M.
    van Dijk, A. P. J.
    Hoendermis, E. S.
    Berger, R. M. F.
    Bresser, P.
    Mulder, B. J. M.
    NETHERLANDS HEART JOURNAL, 2009, 17 (09) : 334 - +
  • [3] Impact of Sildenafil Therapy on Pulmonary Arterial Hypertension in Adults with Congenital Heart Disease
    Lu, Xian-Ling
    Xiong, Chang-Ming
    Shan, Guang-Liang
    Zhu, Xian-Yang
    Wu, Bing-Xiang
    Wu, Guang-Hua
    Liu, Zhi-Hong
    Ni, Xin-Hai
    Cheng, Xian-Sheng
    Gu, Qing
    Zhao, Zhi-Hu
    Zhang, Duan-Zhen
    Li, Wei-Min
    Zhang, Cheng
    Tian, Hong-Yan
    Guo, Ya-Juan
    Guo, Tao
    Liu, Hong-Min
    Zhang, Wei-Jun
    Gu, Hong
    Huang, Shi-An
    Chen, Jian-Ying
    Wu, Wei-Feng
    Huang, Kai
    Li, Jian-Jun
    He, Jian-Guo
    CARDIOVASCULAR THERAPEUTICS, 2010, 28 (06) : 350 - 355
  • [4] Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
    Schuuring, Mark J.
    Vis, Jeroen C.
    Duffels, Marielle G.
    Bouma, Berto J.
    Mulder, Barbara J. M.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 359 - 366
  • [5] Eisenmenger syndrome and other types of pulmonary arterial hypertension related to adult congenital heart disease
    Favoccia, Carla
    Constantine, Andrew H.
    Wort, Stephen J.
    Dimopoulos, Konstantinos
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (06) : 449 - 459
  • [6] Pulmonary arterial hypertension treatment with bosentan in pediatric patients with congenital heart disease
    Romero Jimenez, Rosa M.
    Garcia Sanchez, Raquel
    Gimenez Manzorro, Alvaro
    Martinez Fernandez-Llamazares, Cecilia
    Sanjurjo Saez, Maria
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 347 - 347
  • [7] Acute Hemodynamic Effects of Single Oral Dose of Bosentan in Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Disease
    Ajami, Gholamhossein
    Ahmadipour, Maryam
    Amoozgar, Hamid
    Bourzoee, Mohammad
    Cheriki, Sirous
    Shakiba, Ali Mohammad
    Edraki, Mohammad Reza
    CONGENITAL HEART DISEASE, 2014, 9 (04) : 343 - 348
  • [8] Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease
    Gatzoulis, Michael A.
    Barst, Robyn
    Fineman, Jeffrey
    Galie, Nazzareno
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S19 - S25
  • [9] Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism
    M. G. J. Duffels
    M. N. van der Plas
    S. Surie
    M. M. Winter
    B. J. Bouma
    M. Groenink
    A. P. J. van Dijk
    E. S. Hoendermis
    R. M. F. Berger
    P. Bresser
    B. J. M. Mulder
    Netherlands Heart Journal, 2009, 17 : 334 - 338
  • [10] The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
    Kuang, Hong-Yu
    Wu, Yu-Hao
    Yi, Qi-Jian
    Tian, Jie
    Wu, Chun
    Shou, We Nian
    Lu, Tie-Wei
    MEDICINE, 2018, 97 (10)